

ORIGINAL RESEARCH

Edwin Chandrasekar, MPPM; Sharon Song, PhD; Matthew Johnson, MPH;
Aaron M. Harris, MD, MPH; Gary I. Kaufman, MD; David Freedman, MD;
Michael T. Quinn, PhD; Karen E. Kim, MD, MS

Results

PEER REVIEWED

Introduction

Conclusions

Methods



The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

Procedures

Data analysis

Table 1. Demographic Characteristics and Testing Results of African-Born Persons Recruited Through a Chain Referral Sampling Strategy, Chicago Metropolitan Area, 2012–2014

Variable	Number (%) (N = 445)	Clinical Screening Location (%) (N = 386)	Nonclinical Screening Location (%) (N = 59)	P Value
Sex				
Male	219 (49)	186 (48)	33 (56)	.33
Female	226 (51)	200 (52)	26 (44)	
Race				
Black	411 (93)	353 (91)	58 (98)	<.004
White	11 (2)	11 (3)	0	
Other	12 (3)	11 (3)	1 (2)	
Not indicated	11 (2)	11 (3)	0	
Age, y				
<18	90 (20)	90 (23)	0	<.001
18–39	190 (43)	174 (45)	16 (27)	
40–64	156 (35)	115 (30)	41 (70)	
≥65	9 (2)	7 (2)	2 (3)	
Health insurance status				
Yes	354 (80)	330 (86)	24 (41)	.005
No	83 (19)	51 (13)	32 (54)	
Unknown	8 (2)	5 (1)	3 (5)	
Residency in United States, y				
<10	310 (70)	300 (78)	10 (17)	<.001
10–19	29 (6)	0	29 (49)	
20–29	14 (3)	0	14 (24)	
Unknown	92 (21)	86 (22)	6 (10)	

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

Table 2. Proportion of Hepatitis B Surface Antigen and Potential Exposure Based on Hepatitis B Core Antibody Positivity Among African-Born Persons by Country of Origin, Chicago Metropolitan Area, 2012–2014

Country of Origin	HBsAg and Anti-HBc Results		
	HBsAg Positive, No. (%)	Anti-HBc Positive ^a , No. (%)	Total No. Tested
Algeria	0	0	2
Benin	0	0	1
Cameroon	0	0	4
Central Africa Republic	3 (43)	0	7
Chad	0	0	6
Democratic Republic of the Congo	3 (5)	21 (11)	62
Cote d'Ivoire (Ivory Coast)	1 (33)	2 (1)	3
Djibouti	2 (50)	0	4
Egypt	0	2 (1)	3
Eritrea	0	0	6
Ethiopia	2 (4.5)	2 (1)	44
Ghana	4 (8)	1 (.05)	49
Guinea	0	0	1
Kenya	0	6 (3)	11
Liberia	1 (33)	0	3
Libyan Arab Jamah	0	2 (1)	4
Malawi	0	0	2
Mauritania	0	1 (.05)	2
Morocco	0	0	4
Mozambique	0	0	3
Namibia	0	1 (.05)	5
Niger	0	0	2
Nigeria	4 (7)	4 (2)	58
Rwanda	1 (4)	1 (.05)	26
Sierra Leone	1 (50)	1 (.05)	2
Somalia	7 (15)	13 (7)	47
Sudan	5 (25)	4 (2)	20
Syria	0	0	2
Tanzania	0	1 (.05)	2
Togo	0	1 (.05)	8
Uganda	0	6 (3)	13
Zaire	1 (3)	0	34
Zimbabwe	0	0	2
Other Africa ^b	0	3 (1.5)	3
Totals	35 (8)	72 (37)	445

Abbreviations: anti-HBc, hepatitis B core antibody; anti-HBs, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen.

^a 194 participants had serological data for all 3 tests (HBsAg, anti-HBc, anti-HBs).

^b Three participants indicated "Africa" rather than a specific country.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.